226 related articles for article (PubMed ID: 34479103)
41. Novel Agents in Waldenström Macroglobulinemia.
Sarosiek S; Castillo JJ
Hematol Oncol Clin North Am; 2023 Aug; 37(4):751-760. PubMed ID: 37198054
[TBL] [Abstract][Full Text] [Related]
42. Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors.
Arthur R; Valle-Argos B; Steele AJ; Packham G
Explor Target Antitumor Ther; 2020 Jun; 1(3):131-152. PubMed ID: 32924028
[TBL] [Abstract][Full Text] [Related]
43. Identification of novel inhibitors targeting TIRAP interactions with BTK and PKCδ in inflammation through an in silico approach.
Rajpoot S; Srivastava G; Siddiqi MI; Saqib U; Parihar SP; Hirani N; Baig MS
SAR QSAR Environ Res; 2022 Mar; 33(3):141-166. PubMed ID: 35174746
[TBL] [Abstract][Full Text] [Related]
44. Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review.
Kifle ZD
Metabol Open; 2021 Sep; 11():100116. PubMed ID: 34345815
[TBL] [Abstract][Full Text] [Related]
45. Lysine-Reactive
Kawano M; Murakawa S; Higashiguchi K; Matsuda K; Tamura T; Hamachi I
J Am Chem Soc; 2023 Dec; 145(48):26202-26212. PubMed ID: 37987622
[TBL] [Abstract][Full Text] [Related]
46. Synthesis and application of small molecules approved for the treatment of lymphoma.
Guo YY; Zhang JY; Sun JF; Nie P; Gao H
Eur J Med Chem; 2023 Dec; 261():115835. PubMed ID: 37801827
[TBL] [Abstract][Full Text] [Related]
47. Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis.
Hopkins BT; Bame E; Bajrami B; Black C; Bohnert T; Boiselle C; Burdette D; Burns JC; Delva L; Donaldson D; Grater R; Gu C; Hoemberger M; Johnson J; Kapadnis S; King K; Lulla M; Ma B; Marx I; Magee T; Meissner R; Metrick CM; Mingueneau M; Murugan P; Otipoby KL; Polack E; Poreci U; Prince R; Roach AM; Rowbottom C; Santoro JC; Schroeder P; Tang H; Tien E; Zhang F; Lyssikatos J
J Med Chem; 2022 Jan; 65(2):1206-1224. PubMed ID: 34734694
[TBL] [Abstract][Full Text] [Related]
48. Novel 5-Substituted Oxindole Derivatives as Bruton's Tyrosine Kinase Inhibitors: Design, Synthesis, Docking, Molecular Dynamics Simulation, and Biological Evaluation.
Velavalapalli VM; Maddipati VC; Gurská S; Annadurai N; Lišková B; Katari NK; Džubák P; Hajdúch M; Das V; Gundla R
ACS Omega; 2024 Feb; 9(7):8067-8081. PubMed ID: 38405484
[TBL] [Abstract][Full Text] [Related]
49. Bruton tyrosine kinase inhibitors: can they be optimized for the treatment of neuroinflammatory disorders?
Visentin A; Puthenparampil M; Briani C
Expert Opin Investig Drugs; 2023; 32(12):1105-1111. PubMed ID: 38153100
[TBL] [Abstract][Full Text] [Related]
50. Reduced clone size upon BTK inhibitor resistance mutations relates to toxicity caused by inherited PLCG2 gain-of-function variations.
Smith CIE; Zain R
Eur J Haematol; 2024 Jul; 113(1):130-131. PubMed ID: 38529725
[No Abstract] [Full Text] [Related]
51. Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors.
Qi J; Endres S; Yosifov DY; Tausch E; Dheenadayalan RP; Gao X; Müller A; Schneider C; Mertens D; Gierschik P; Wist M; Jebaraj BMC; Stilgenbauer S
Blood Adv; 2023 Oct; 7(19):5698-5702. PubMed ID: 36661329
[No Abstract] [Full Text] [Related]
52. The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review.
Rezaei M; Barati S; Babamahmoodi A; Dastan F; Marjani M
Curr Ther Res Clin Exp; 2022; 96():100658. PubMed ID: 34931090
[TBL] [Abstract][Full Text] [Related]
53. Design, synthesis, and evaluation of BTK-targeting PROTACs with optimized bioavailability
Sun Y; Yang Z; Zhang Z; Li Z; Guo L; Pan H; Luo X; Liu D; Rao Y
RSC Med Chem; 2023 Aug; 14(8):1562-1566. PubMed ID: 37593574
[TBL] [Abstract][Full Text] [Related]
54. BTK degraders tackle drug resistance.
Villanueva MT
Nat Rev Drug Discov; 2024 Mar; 23(3):173. PubMed ID: 38336888
[No Abstract] [Full Text] [Related]
55. Important players in carcinogenesis as potential targets in cancer therapy: an update.
Hermanowicz JM; Kwiatkowska I; Pawlak D
Oncotarget; 2020 Aug; 11(32):3078-3101. PubMed ID: 32850012
[TBL] [Abstract][Full Text] [Related]
56. High-risk stays high-risk: Bruton tyrosine kinase inhibitors in B-cell malignancies.
Al-Sawaf O
Haematologica; 2024 Mar; ():. PubMed ID: 38450529
[TBL] [Abstract][Full Text] [Related]
57. Novel BTK Inhibitors for Treating Autoimmune Disorders and Cancer.
Sabnis RW
ACS Med Chem Lett; 2022 May; 13(5):759-760. PubMed ID: 35586429
[No Abstract] [Full Text] [Related]
58. Correction: Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer.
Gut; 2024 Jun; ():. PubMed ID: 38866472
[No Abstract] [Full Text] [Related]
59. Discovery of novel BTK PROTACs for B-Cell lymphomas.
Zhao Y; Shu Y; Lin J; Chen Z; Xie Q; Bao Y; Lu L; Sun N; Wang Y
Eur J Med Chem; 2021 Dec; 225():113820. PubMed ID: 34509879
[TBL] [Abstract][Full Text] [Related]
60. Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic.
Hu Z; Crews CM
Chembiochem; 2022 Jan; 23(2):e202100270. PubMed ID: 34494353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
